REGENXBIO develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector. read more
REGENXBIO CEO & Leadership Team Ratings
Ken Mills and the REGENXBIO leadership team are scored a B- by 9 employees placing it in the Top 40% of companies sized 1-10 Employees on Comparably. The Leadership score includes details about how employees evaluate their executive team, CEO and manager.
Based on 42 ratings, the Leadership score of 75/100 combines employee feedback on their CEO (72/100), Manager (73/100), and Executive Team (61/100).
Ken Mills REGENXBIO CEO Rating
Top 40% Compared to other companies of similar size in Washington, DCB-
72 / 100
Ken Mills the CEO of REGENXBIO received an average score of 72 from REGENXBIO employees.REGENXBIO Manager Rating
Top 40% Compared to other companies of similar size in Washington, DCB-
73 / 100
REGENXBIO Executive Team Rating
Bottom 25% Compared to other companies of similar size in Washington, DCD+
61 / 100
×